Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Systemic thrombolysis in ischemic stroke].

V I Skvortsova, G N Golukhov, L V Gubskiĭ

    Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova
    |February 6, 2007
    PubMed
    Summary

    Recombinant tissue plasminogen activator (rt-PA) effectively treats acute ischemic stroke. This study shows thrombolysis improved outcomes for 64.2% of patients, demonstrating its value in stroke management.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    [Fortelyzin in the treatment of acute ischemic stroke in patients ≥80 years old: data from the observational study FORPI registry].

    Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·2026
    Same author

    [Drug-drug interactions with Mexidol in patients with ischemic stroke: Analysis of data from randomized clinical trials].

    Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·2026
    Same author

    Deciphering the genetic control of immune cell function at single-cell resolution: Disease-Specific Cis-eQTLs analysis of COVID-19.

    Immunogenetics·2026
    Same author

    [The first experience of using tenecteplase for the thrombolytic therapy in ischemic stroke in the Russian Federation].

    Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·2026
    Same author

    [Fortelizin in bridging therapy of acute ischemic stroke: data from the observational study FORPI registry].

    Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·2026
    Same author

    [Fortelyzin for acute ischaemic stroke treatment in an extended (4.5 to 24 hours from the onset of symptoms) time window: data from the observational study FORPI registry].

    Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·2026

    Area of Science:

    • Neurology
    • Cardiovascular Medicine
    • Emergency Medicine

    Background:

    • Acute ischemic stroke requires rapid intervention.
    • Intravenous recombinant tissue plasminogen activator (rt-PA) is a standard treatment.
    • Limited data exists on rt-PA implementation in the Russian Federation.

    Purpose of the Study:

    • To present the initial results of rt-PA thrombolysis for acute ischemic stroke in Russia.
    • To evaluate the efficacy and safety of rt-PA in a real-world clinical setting.

    Main Methods:

    • Retrospective analysis of 14 acute ischemic stroke patients treated with rt-PA.
    • Standard rt-PA dosage (0.9 mg/kg) administered intravenously.
    • Monitoring of "door-to-needle" time, clinical improvement (NIHSS), and hemorrhagic transformation.

    Related Experiment Videos

    Main Results:

    • Mean "door-to-needle" time was 50 minutes.
    • Clinical improvement observed in 64.2% of patients within 24 hours.
    • Hemorrhagic transformation occurred in 42.8%, mostly asymptomatic.
    • 50% of patients achieved a modified Rankin Scale score of 0-1 at 3 months.

    Conclusions:

    • Intravenous rt-PA thrombolysis is feasible and effective in the Russian Federation.
    • Early thrombolysis significantly improves functional outcomes in acute ischemic stroke patients.
    • Continued implementation of rt-PA can enhance stroke care and patient prognosis.